Navigation Links
Brain Scans Using New Dye May Predict Alzheimer's
Date:7/11/2012

WEDNESDAY, July 11 (HealthDay News) -- Brain scans using a new radioactive dye can detect early evidence of Alzheimer's disease in people who show little or no signs of the disease and may help predict future mental decline, a new study says.

It included 151 people who completed thinking and memory tests and underwent a PET (positron emission tomography) brain scan with the new dye called florbetapir (Amyvid). They were then followed for three years.

The dye binds to amyloid plaques that occur in the brains of people with Alzheimer's disease, enabling doctors to see if patients have the plaques and how much.

At the start of the study, 69 patients had normal mental function, 51 had mild impairment and 31 had Alzheimer's disease.

After 18 months, thinking and memory test results of patients who started off with mild impairment and whose brain scans revealed evidence of amyloid plaques worsened to a greater degree than those who had mild impairment but had no evidence of plaques at the start of the study.

The patients with amyloid plaques at the outset were also more likely to go on to develop Alzheimer's. After three years, 29 percent of the plaque-positive patients with mild impairment developed Alzheimer's compared with 10 percent of those with mild impairment who had no plaques at the start of the study.

Among participants with normal mental function at the start of the study, those with evidence of brain plaques showed more mental decline after 18 months than those with no sign of plaques.

"Even at a short follow-up of 18 months we can see how the presence of amyloid plaques affects cognitive [thinking] function," study co-leader Dr. P. Murali Doraiswamy, a professor of psychiatry at Duke University, said in a university news release. "Most people who come to the doctor with mild impairment really want to know the short-term prognosis and potential long-term effect."

There is no cure for Alzheimer's, but being able to detect the early stages of Alzheimer's could help advance efforts to find ways to fight the disease and enhance the care and treatment of current patients, he explained.

"For the most part we have been blind about who would progress and who wouldn't, so this approach is a step toward having a biomarker that predicts risk of decline in people who are experiencing cognitive impairment," Doraiswamy said.

The study, published online July 11 in the journal Neurology, was funded by Eli Lilly/Avid Radiopharmaceuticals, which markets Amyvid. Doraiswamy receives advisory and speaker fees from Lilly/Avid.

According to the U.S. Food and Drug Administration, Amyvid was approved in April for use in imaging tests for patients being evaluated for Alzheimer's.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about Alzheimer's disease.

-- Robert Preidt

SOURCE: Duke University, news release, July 11, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Epilepsy Leads to More Brain Abnormalities Over Time
3. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
4. Why is traumatic brain injury increasing among the elderly?
5. Brain Falters Near End of Life, but Games, Puzzles Might Slow Decline
6. Dental X-Rays May Be Linked to Benign Brain Tumors
7. Nonsurgical Method to Measure Brain Pressure Shows Promise
8. Researchers Map Brain Regions Linked to Intelligence
9. Football-related catastrophic brain injuries on the rise
10. Brain Tumor Vaccine Shows Promise in Early Trial
11. Brain Surgery Might Ease Tough-to-Treat OCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... ... past six years, Lightning Labels has sent out a call for users of its custom ... creativity of their designs. Submissions this year were open from May 18 to July 1 ... winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, a ... of modern life continually makes more demands on time and energy, people are finding ... people in vicious high/low cycles and can also cause long term health issues. More ...
(Date:8/21/2017)... ... August 22, 2017 , ... ... I. Stevens as a 2017-2018 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting more ...
(Date:8/21/2017)... ... 2017 , ... Marathon running has surged in popularity in ... running increases exposure to ultraviolet radiation, a carcinogen that promotes skin cancer. Studies ... half may be adequately protecting themselves with proper clothing and sunscreen. , ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results ... reported second quarter net sales of $1.954 billion, an ... an increase of 2.1% on a constant currency basis.  ... LDR Holding Corporation acquisition, second quarter 2017 revenues decreased ... on a constant currency basis. ...
(Date:7/26/2017)... Colo. , July 26, 2017 E.I. ... Guttridge and the Bimini SharkLab to custom design the worlds ... images of sharks in their native habitat. In preparation ... Discovery Channel,s Shark Week, Dr. Guttridge approached EIMI ... take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced ... Altemia TM , an oral therapy for pediatric patients ... (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, ... Altemia TM in pediatric patients aged 5-17 years ... "The completion of ...
Breaking Medicine Technology: